Individualized surveillance plans for the skeletal, pulmonary, soft-tissue, and other manifestations of PS should be developed according to patientsâ€™ specific needs.

Because of the predisposition to a range of tumors (most of which are benign) patients should be monitored by their primary care provider with regular evaluations including a directed medical history and examination.
